MustGrow Biologics Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Corey J. Giasson
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Address
- 201 1st Avenue South Saskatoon SK Canada S7K 1J5
- IPO Date
- Nov 21, 2019
- Website
- mustgrow.ca
- Similar Companies
- Business
- MustGrow Biologics Corp. (TSXV:MGRO; OTCQB:MGROF), founded in 2014 and headquartered in Saskatoon, Saskatchewan, Canada, develops and commercializes innovative biological and regenerative agriculture solutions derived from mustard seed to replace synthetic chemicals and fertilizers; its proprietary TerraMG platform offers soil biocontrol products treating soil-borne pests, diseases, nematodes and weeds in crops including fruits and vegetables, preplant soil biofumigants, bioherbicides, postharvest potato sprout suppression and pathogen control technologies; TerraSante provides organic biofertility through vegetable proteins and nutrients that stimulate beneficial microbial activity and soil health; through its NexusBioAg division, the company distributes third-party crop nutrition solutions such as micronutrients, nitrogen stabilizers, biostimulants, adjuvants and folars primarily in North America. MustGrow holds approximately 112 issued and pending patents supporting its platform across agriculture, home and garden, storage preservation, and potential animal and human health applications, while targeting organic and sustainable farming markets globally amid regulatory restrictions on synthetic agchems. The company maintains an exclusive commercial license agreement with Bayer AG, signed in December 2023, to commercialize preplant soil biocontrol technologies in Europe, the Middle East and Africa; it completed the acquisition of NexusBioAg assets from Univar Solutions Canada Ltd. on December 31, 2024 for approximately C$1.7 million in deferred cash plus 2025-2026 earn-outs to integrate sales, marketing and distribution capabilities; recent advancements include California organic registration for TerraSante in May 2024 enabling initial U.S. sales ramp-up in 2025-2026, alongside securing a C$2.0 million line of credit with CIBC guaranteed by EDC in September 2025 and reporting record Q3-2025 results.
MustGrow Announces First Quarter 2026 Financial Results
MustGrow Announces Non-Brokered LIFE Offering of Approximately $2 Million
MustGrow Biologics receives TerraSante approvals in Texas, Utah and Montana
MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility Product
Huawei Technologies unveils new design chip strategy amid intensifying global competition
MustGrow Announces Market Awareness Services and Investor Relations Agreements
Rivian beats earnings estimates amid R2 production ramp
Sandisk could blow past its own guidance as NAND pricing hits triple digits
MustGrow Biologics reports jump in revenue as TerraSante US sales drive growth
MustGrow Announces 2025 Financial Results
MustGrow wins Georgia approval for TerraSante biofertility product
MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product
At 95, Warren Buffett refuses to stop: The curious case of the never-retired billionaire
Carvana surges as Jefferies flags strong unit growth, pricing momentum
MustGrow pivots to US TerraSante growth
Nvidia’s China question is back and the clock is ticking
Amazon expands access to digital assistant Alexa+
MustGrow Biologics reports positive field trial results for TerraMG in canola production
Shopify gears up for strong 2025 finish as analysts eye margins and AI strategy
MustGrow's Canola Field Trials Demonstrate Clubroot Disease Suppression; Improved Canola Yield with Healthier Root Systems